Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kodiak Sciences Inc (KOD)

Kodiak Sciences Inc (KOD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,263,073
  • Shares Outstanding, K 53,048
  • Annual Sales, $ 0 K
  • Annual Income, $ -176,210 K
  • EBIT $ -223 M
  • EBITDA $ -196 M
  • 60-Month Beta 2.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 53.80

Options Overview Details

View History
  • Implied Volatility 113.19% (-2.60%)
  • Historical Volatility 76.58%
  • IV Percentile 25%
  • IV Rank 14.14%
  • IV High 422.80% on 03/21/25
  • IV Low 62.19% on 09/08/25
  • Expected Move (DTE 4) 3.57 (14.99%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 244
  • Volume Avg (30-Day) 168
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 6,598
  • Open Int (30-Day) 6,657
  • Expected Range 20.24 to 27.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.08
  • Number of Estimates 4
  • High Estimate -0.86
  • Low Estimate -1.20
  • Prior Year -0.84
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.05 +31.91%
on 11/13/25
26.21 -9.16%
on 12/09/25
+3.56 (+17.58%)
since 11/12/25
3-Month
9.10 +161.65%
on 09/17/25
26.21 -9.16%
on 12/09/25
+14.56 (+157.41%)
since 09/12/25
52-Week
1.92 +1,140.10%
on 04/09/25
26.21 -9.16%
on 12/09/25
+15.44 (+184.47%)
since 12/12/24

Most Recent Stories

More News
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

PALO ALTO, Calif. , Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025....

KOD : 23.81 (-1.33%)
Kodiak Sciences to Present at Upcoming Investor Conferences

PALO ALTO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...

KOD : 23.81 (-1.33%)
Stocks Settle Mostly Higher on Government Reopening Optimism

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%. December E-mini...

AMAT : 259.21 (-4.04%)
AVGO : 359.93 (-11.43%)
MRK : 100.30 (+1.30%)
RGTI : 25.84 (-3.87%)
$IUXX : 25,196.73 (-1.91%)
AMGN : 317.74 (+0.11%)
PFE : 25.85 (+0.19%)
ELV : 359.07 (-0.32%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-105 (+0.14%)
CRWV : 78.59 (-10.06%)
VRTS : 169.14 (+0.49%)
Dow and S&P Rise as Nasdaq Faces Selling Pressure

The S&P 500 Index ($SPX ) (SPY ) today is up +0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. US stock indexes are mixed...

AMAT : 259.21 (-4.04%)
AVGO : 359.93 (-11.43%)
RKLB : 61.49 (-3.21%)
RGTI : 25.84 (-3.87%)
$IUXX : 25,196.73 (-1.91%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-105 (+0.14%)
CRWV : 78.59 (-10.06%)
PSKY : 13.74 (-2.69%)
SRDX : 42.98 (+0.35%)
LRCX : 160.52 (-4.85%)
AMD : 210.78 (-4.81%)
Stocks Pressured by AI Jitters and Signs of US Labor Market Weakness

The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.42%. December E-mini S&P futures...

AMAT : 259.21 (-4.04%)
RKLB : 61.49 (-3.21%)
RGTI : 25.84 (-3.87%)
$IUXX : 25,196.73 (-1.91%)
ZNH26 : 112-105 (+0.14%)
CRWV : 78.59 (-10.06%)
ESZ25 : 6,854.75 (+0.35%)
PSKY : 13.74 (-2.69%)
SRDX : 42.98 (+0.35%)
LRCX : 160.52 (-4.85%)
VSAT : 35.83 (-6.38%)
$DOWI : 48,458.05 (-0.51%)
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...

KOD : 23.81 (-1.33%)
Chardan Capital Keeps Their Hold Rating on Kodiak Sciences (KOD)

In a report released yesterday, Daniil Gataulin from Chardan Capital maintained a Hold rating on Kodiak Sciences, with a price target of $14.00. The company’s shares closed last Friday at $15.06.Elevate...

KOD : 23.81 (-1.33%)
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

PALO ALTO, Calif. , Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...

KOD : 23.81 (-1.33%)
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

PALO ALTO, Calif. , Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...

KOD : 23.81 (-1.33%)
Kodiak Sciences to Present at American Chemical Society Fall 2025

PALO ALTO, Calif. , Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...

KOD : 23.81 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent...

See More

Key Turning Points

3rd Resistance Point 25.96
2nd Resistance Point 25.46
1st Resistance Point 24.63
Last Price 23.81
1st Support Level 23.30
2nd Support Level 22.80
3rd Support Level 21.97

See More

52-Week High 26.21
Last Price 23.81
Fibonacci 61.8% 16.93
Fibonacci 50% 14.06
Fibonacci 38.2% 11.20
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar